{"id":"pre-randomization-dutasteride","safety":{"commonSideEffects":[{"rate":"4-6%","effect":"Erectile dysfunction"},{"rate":"3-5%","effect":"Decreased libido"},{"rate":"1-3%","effect":"Ejaculation disorder"},{"rate":"<1%","effect":"Gynecomastia"},{"rate":"<1%","effect":"Breast tenderness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting 5-alpha reductase, dutasteride reduces DHT levels in the prostate and serum. This leads to shrinkage of the prostate gland and improved urinary flow in men with benign prostatic hyperplasia. The dual inhibition of both isoforms makes it more potent than finasteride, which only inhibits type 2 reductase.","oneSentence":"Dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:10.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms"},{"name":"Male pattern hair loss (androgenetic alopecia)"}]},"trialDetails":[{"nctId":"NCT00537654","phase":"PHASE1","title":"A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-18","conditions":"Prostatic Hyperplasia","enrollment":81},{"nctId":"NCT00431626","phase":"PHASE3","title":"A Clinical Trial Comparing Laser TURP With and Without Dutasteride.","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2006-10","conditions":"Benign Prostatic Hyperplasia","enrollment":4},{"nctId":"NCT00939120","phase":"PHASE4","title":"Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)","status":"COMPLETED","sponsor":"Siami, Paul F., M.D.","startDate":"2009-07","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pre-randomization Dutasteride","genericName":"Pre-randomization Dutasteride","companyName":"Siami, Paul F., M.D.","companyId":"siami-paul-f-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dutasteride inhibits both type 1 and type 2 5-alpha reductase enzymes, blocking the conversion of testosterone to dihydrotestosterone (DHT). Used for Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms, Male pattern hair loss (androgenetic alopecia).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}